Natera (NASDAQ:NTRA) Insider John Fesko Sells 898 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 898 shares of the firm’s stock in a transaction that occurred on Wednesday, October 28th. The shares were sold at an average price of $426.34, for a total transaction of $382,853.32. Following the completion of the sale, the insider owned 195,578 shares in the company, valued at $83,382,724.52. This represents a 0.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Fesko also recently made the following trade(s):

• On Tuesday, October 27th, John Fesko sold 781 shares of Natera stock. The stock was sold at an average price of $406.00, for a total transaction of $317,086.00.
• On Monday, August 10th, John Fesko sold 6,517 shares of Natera stock. The stock was sold at an average price of $321.53, for a total transaction of $2,095,411.01.
• On Monday, August 3rd, John Fesko sold 295 shares of Natera stock. The shares were sold at an average price of $267.99, for a total value of $79,057.05.

Natera Stock Up 2.7%

NASDAQ NTRA opened at $436.00 on Friday. Natera, Inc. has a twelve month low of $181.00 and a twelve month high of $437.41. The company has a market cap of $62.85 billion, a price-to-earnings ratio of -320.59 and a beta of 1.50. The business’s fifty day moving average is $375.27 and its 200 day moving average is $265.54.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The business had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. During the same quarter in the previous year, the company posted ($0.74) EPS. Natera’s quarterly revenue was up 37.7% compared to the same quarter last year. On average, research analysts anticipate that Natera, Inc. will post -1.14 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on NTRA shares. Citigroup raised their price objective on shares of Natera from $365.00 to $480.00 and gave the company a “buy” rating in a report on Tuesday, October 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a report on Thursday, October 15th. Stephens upped their price target on shares of Natera from $305.00 to $350.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Evercore restated an “outperform” rating and issued a $300.00 price target on shares of Natera in a research report on Monday, July 6th. Finally, BTIG Research raised their price target on shares of Natera from $320.00 to $430.00 and gave the company a “buy” rating in a research note on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $394.31.

More Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera presented 25 abstracts at the ESMO oncology conference, highlighting additional Signatera data and supporting the test’s potential commercial and clinical adoption. Natera presents 25 ESMO abstracts
• Positive Sentiment: Investors reacted favorably to Signatera clinical and regulatory wins, which could strengthen Natera’s competitive position in minimal residual disease testing and support future revenue growth. Investors React to Signatera Wins
• Positive Sentiment: The third-quarter outlook centers on continued Signatera volume growth, higher test prices, regulatory progress and expanding Medicare coverage that could benefit Natera’s organ-health business. NTRA Q3 Earnings Preview
• Neutral Sentiment: Natera will release third-quarter 2026 results on November 5 after the market closes, giving investors a near-term catalyst to assess testing volumes, reimbursement trends and profitability. Natera Q3 Results Announcement
• Negative Sentiment: Zacks cautions that Natera may report negative earnings and lacks the typical combination of estimate revisions and momentum associated with a likely earnings beat, raising the risk of volatility around the report. Natera Earnings Beat Outlook
• Negative Sentiment: One valuation analysis estimates NTRA could be about 32% below fair value based on ESMO-related data, suggesting the stock’s gains may have outpaced its fundamentals. Natera Fair Value Analysis
• Negative Sentiment: Two company officers disclosed plans to sell a combined 1,768 shares, including 771 shares valued at approximately $312,000; the transactions are relatively small but may modestly weigh on sentiment. John Fesko Share Sale Solomon Moshkevich Share Sale

Institutional Investors Weigh In On Natera

Institutional investors have recently made changes to their positions in the stock. Greenleaf Trust bought a new position in shares of Natera during the third quarter worth about $240,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Natera in the third quarter valued at approximately $7,545,000. Profund Advisors LLC boosted its holdings in Natera by 5.6% in the third quarter. Profund Advisors LLC now owns 6,553 shares of the medical research company’s stock valued at $2,708,000 after acquiring an additional 348 shares during the last quarter. Vise Technologies Inc. boosted its holdings in Natera by 5.3% in the third quarter. Vise Technologies Inc. now owns 2,010 shares of the medical research company’s stock valued at $831,000 after acquiring an additional 101 shares during the last quarter. Finally, Americana Partners LLC acquired a new stake in Natera during the 3rd quarter valued at approximately $203,000. Institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.